Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease

Exclusion Criteria

• •Significant co-morbid conditions with life expectancy of \< 1 year
• •Serum potassium of \> 5.5 milliequivalents per liter (mEq/L) at screening
• •New York Heart Association Class 3 or 4 heart failure symptoms, known Ejection Fraction (EF) ≤ 30% or hospital admission for heart failure within the past 3 months
• •Factors judged to limit adherence to interventions based on appointment attendance and medication treatment compliance; PI will make this determination
• •Current participation in another medical intervention study
• •Known to be pregnant or planning to become pregnant or currently breastfeeding; determined by self-report and medical record history. A urine pregnancy test will be completed for individuals of childbearing potential before administering the study drug, and repeated thereafter at every study visit (\~ every 3-4 months)
• •History of dementia documented in the medical record
• •On anticoagulants or immunosuppression
• •Under treatment for cancer
• •Delayed gastric emptying or similar GI conditions Non-English-speaking individuals are excluded in this randomized phase of the study because the lack of English proficiency will affect a subject's ability to report problems or adverse events. If a patient cannot read, the consent form will be read to them by the research coordinator.